Head-to-head evidence
Diastat vs Midazolam (Nayzilam)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: GABA-A receptor · full Epilepsy pipeline
Diastat
Marketed by Bausch Health
NCT03953820 · Phase 1/2 · completed
The study randomized participants to treatment sequences and used Diastat as an active comparator, but it was open-label and small, with 31 randomized participants. Its primary endpoints were pharmacokinetic measures rather than clinical seizure outcomes, and the registry does not clearly report whether the primary comparison met its prespecified statistical criteria.
Midazolam (Nayzilam)
Marketed by UCB
NCT01390220 · Phase 3 · terminated
This was a randomized, triple-blind, placebo-controlled trial in 201 patients, and the primary outcome, control of a seizure cluster with no recurrence, was reached significantly more often with midazolam than with placebo (72 of 134 patients vs 23 of 67, p=0.011).
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Diastat's landscape · Midazolam (Nayzilam)'s landscape